The Comparison of RhoC and PI3K Gene Expression on the Breast Cancer Tissue and Benign Tumour Tissue


  • Dessy Arisanty Department of Biochemistry, Faculty of Medicine, Andalas University, Padang, Indonesia
  • Wirsma Arif Harahap Division of Surgical Oncology, Medical School of Dr. M. Djamil Hospital, Andalas University, Padang, Indonesia
  • Daan Khambri Division of Surgical Oncology, Medical School of Dr. M. Djamil Hospital, Andalas University, Padang, Indonesia
  • Rony Rustam Division of Surgical Oncology, Medical School of Dr. M. Djamil Hospital, Andalas University, Padang, Indonesia
  • Gestina Aliska Department Farmacology, Faculty of Medicine, Andalas University, Padang, Indonesia
  • Afifatul Achyar Biomedical Laboratory, Molecular Division, Faculty of Medicine, Andalas University, Padang, Indonesia
  • Juane Plantika Menra Biomedical Laboratory, Molecular Division, Faculty of Medicine, Andalas University, Padang, Indonesia



RhoC gene, PI3K gene, Real-time PCR (qPCR), Cloning, Vector


BACKGROUND: The expression of a gene is a process that conveys information of genes to synthesise gene product is functional. Alterations of the molecular biology in breast cancer are very complex because of many factors play a role in the tumorigenesis. RhoC is a prometastases gene. The PI3K gene is crucial in the regulation of multiple cellular functions, including cell growth, proliferation, metabolism and angiogenesis.
AIM: This study aims to compare of RhoC and PI3K gene expression on the breast cancer tissue and benign tumour tissue.
MATERIAL AND METHODS: Expression of the RhoC and PI3K genes was carried out with qPCR. The absolute quantification method was using breast cancer tissue. As a comparison, benign tumours (FATs) tissue was carried out. The standard curves were obtained from cloning target genes, which were inserted into the gGEMT-easy vector from E. coli. The gene expression data was carried out by t-test to see the mean difference between the expression of breast cancer tissue and benign tumours (FATs) with a value of p ≤ 0.005 in RhoC and PI3K gene expression. And the relationship between expressions was done by Pearson correlation test.
RESULTS: The results showed that it was found that PI3K gene expression on breast cancer tissue was higher than the number in a benign tumour (fibroadenoma mammae) as an endogenous control. And also, the expression of RhoC is much lower on breast cancer tissue compared with a benign tumour.
CONCLUSION: This study concluded that expression of RhoC affects the expression of PI3K so that the thing this is what causes the proliferation and began to provide support aggressive cancer cells in the breast.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Utami VL, Muhartono, Fiana DN, Soleha TU. Characteristic of carcinoma mammae at RSUD Dr. H. Abdul Moeloek Bandar Lampung 2010-2012. J Agromed Unila. 2014; 1(1): 1-7.

Murshid KR. A review of mastalgia in patients with fibrocystic breast changes and the non-surgical treatment options. Journal of Taibah University Medical Sciences. 2011; 6(1):1-8.

Word Health Organization, 2015. Cancer. (http://www.who. int/mediacentre/factsheets/fs297/en/index.html), diakses 31 Oktober 2015).

Underwood JCE, Cross SS. Patologi umum dan sistemik. Edisi ke-2. Jakarta: EGC. 2010: 543-66.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortetâ€Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65(2):87-108. PMid:25651787

Kementrian Kesehatan Republik Indonesia. Pedoman Teknis Pengendalian Kanker Payudara dan Kanker Leher Rahim. Keputusan Menteri Kesehatan Republik Indonesia Nomor 796/ Menkes/ SK/ VII/. Jakarta, Hal 4, 2010.

Liu Z, Zhu J, Cao H, Ren H, Fang X. miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. International journal of oncology. 2012; 40(5):1553-60.

Van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer research. 2000; 60(20):5832-8.

Srivastava S, Ramdass B, Nagarajan S, Rehman M, Mukherjee G, Krishna S. Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. British journal of cancer. 2010; 102(1):196-205. PMid:19953094 PMCid:PMC2813755

Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Laboratory investigation. 2003; 83(6):861. PMid:12808121

Yang H, ZHOu J, Mi J, Ma K, Fan Y, Ning J, Wang C, Wei X, Zhao H, Li E. HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma. Oncology reports. 2015; 34(4):1681-91. PMid:26260613 PMCid:PMC4564083

Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics. 2006; 7(8):606. PMid:16847462

Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature reviews Drug discovery. 2005; 4(12):988-1004. PMid:16341064

Rafalski VA, Brunet A. Energy metabolism in adult neural stem cell fate. Progress in neurobiology. 2011; 93(2):182-203. PMid:21056618

Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer research. 2004; 64(19):7002-10. PMid:15466193

Chen YL, Law PY, Loh HH. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Current Medicinal Chemistry-Anti-Cancer Agents. 2005; 5(6):575-89. PMid:16305480

Xue B, Huang W, Yuan X, Xu B, Lou Y, Zhou Q, Ran F, Ge Z, Li R, Cui J. YSY01A, a novel proteasome inhibitor, induces cell cycle arrest on G2 phase in MCF-7 cells via eRα and PI3K/Akt pathways. Journal of Cancer. 2015; 6(4):319-326. PMid:25767601 PMCid:PMC4349871

Kuger S, Cörek E, Polat B, Kämmerer U, Flentje M, Djuzenova CS. Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radio sensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions. Breast Cancer. 2014; 8:39-49. PMid:24678241 PMCid:PMC3964191

Whelan JA, Russell NB, Whelan MA. A method for the absolute quantification of cDNA using real-time PCR. Journal of immunological methods. 2003; 278(1-2):261-9.

Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014; 343(6178):1466-70. PMid:24675953 PMCid:PMC4074902

Wang Y, Li Z, Zhao X, Zuo X, Peng Z. miR-10b promotes invasion by targeting HOXD10 in colorectal cancer. Oncology letters. 2016; 12(1):488-94. PMid:27347170 PMCid:PMC4907168

Ikoma T, Takahashi T, Nagano S, Li YM, Ohno Y, Ando K, Fujiwara T, Fujiwara H, Kosai KI. A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clinical Cancer Research. 2004; 10(3):1192-200. PMid:14871999

Kitzing TM, Wang Y, Pertz O, Copeland JW, Grosse R. Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC. Oncogene. 2010; 29(16):2441-8. PMid:20101212

Vega FM, Fruhwirth G, Ng T, Ridley AJ. RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. The Journal of cell biology. 2011; 193(4):655-65. PMid:21576392 PMCid:PMC3166870

Sun HW, Tong SL, He J, Wang Q, Zou L, Ma SJ, Tan HY, Luo JF, Wu HX. RhoA and RhoC-siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway. World journal of gastroenterology: WJG. 2007; 13(25):3517-22. PMid:17659701 PMCid:PMC4146790

Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer treatment reviews. 2014; 40(7):862-71. PMid:24774538

Ryan J, Curran CE, Hennessy E, Newell J, Morris JC, Kerin MJ, Dwyer RM. The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One. 2011; 6(1):e16023. PMid:21283523 PMCid:PMC3023714

Kleer CG, Van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. The American journal of pathology. 2002; 160(2):579-84.



How to Cite

Arisanty D, Harahap WA, Khambri D, Rustam R, Aliska G, Achyar A, Menra JP. The Comparison of RhoC and PI3K Gene Expression on the Breast Cancer Tissue and Benign Tumour Tissue. Open Access Maced J Med Sci [Internet]. 2019 Jul. 2 [cited 2023 Oct. 3];7(12):1911-6. Available from:



A - Basic Science

Most read articles by the same author(s)

1 2 > >>